---
title: "The artemisinin sector sees a short-term surge, Rundu Pharma hits the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233380307.md"
description: "The artemisinin sector saw a short-term surge, with Rundu Pharma hitting the limit-up, followed by gains in Baihua Medicine, HISUN, ZMC, Kunming Pharmaceutical Group, and CR Double-Crane"
datetime: "2025-03-27T02:58:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233380307.md)
  - [en](https://longbridge.com/en/news/233380307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233380307.md)
generator: "portal-rs"
---

# The artemisinin sector sees a short-term surge, Rundu Pharma hits the limit up

The artemisinin sector saw a short-term surge, with Rundu Pharma hitting the limit up, followed by gains in Baihua Pharmaceutical, HISUN, ZMC, Kunming Pharmaceutical Group, and CR Double-Crane

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)
- [600062.CN](https://longbridge.com/en/quote/600062.CN.md)
- [600267.CN](https://longbridge.com/en/quote/600267.CN.md)
- [002923.CN](https://longbridge.com/en/quote/002923.CN.md)
- [600422.CN](https://longbridge.com/en/quote/600422.CN.md)
- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)

## Related News & Research

- [Fugro joins EU OCEANITY project to develop Europe Digital Twin Ocean applications](https://longbridge.com/en/news/298181534.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [14:09 ETXiamenAir launches new intercontinental route with inaugural Xiamen-London flight](https://longbridge.com/en/news/298138660.md)
- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)
- [05:37 ETGan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe](https://longbridge.com/en/news/297892423.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**